Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Eur Urol. 2023 May 19;84(1):127–137. doi: 10.1016/j.eururo.2023.04.020

Table 2 –

Case-case ORs for the associations of sex and rs2896518 mutation with FGFR3 somatic mutations a

Study Female versus male rs2896518-A risk allele
Cases (n) OR (95% CI) b Cases (n) OR (95% CI) b
FGFR3 wt FGFR3 M+ FGFR3 wt FGFR3 M+
SBCS 551 391 1.18 (0.80–1.73) 480 338 1.07 (0.84–1.37)
NEBCS 171 174 1.59 (0.96–2.64) 132 142 1.46 (0.96–2.21)
UROMOL 401 460 1.35 (0.98–1.87) 291 373 1.23 (0.95–1.59)
Meta-analysis 1123 1025 1.33 (1.07–1.66) 885 816 1.19 (1.01–1.40)
p value 0.011 0.039

OR = odds ratio; CI = confidence interval; wt = wild type; M+ = mutation; SBCS = Spanish Bladder Cancer EPICURO study; NEBCS = New England Bladder Cancer Study.

a

Details on FGFR3 mutation analyses are provided in the Supplemental material.

b

Unadjusted OR for the odds of having an FGFR3 mutation; additionally adjusted ORs are provided in Supplementary Table 8.